We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

DURECT Corp (DRRX) USD0.0001

Sell:$0.92 Buy:$1.00 Change: $0.092 (10.72%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.92
Buy:$1.00
Change: $0.092 (10.72%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$0.92
Buy:$1.00
Change: $0.092 (10.72%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

DURECT Corporation is a late-stage biopharmaceutical company. The Company is engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Its lead drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in alcoholic hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Therapy designation, and metabolic dysfunction-associated steatohepatitis (MASH) is also being explored. Its commercial pharmaceutical product includes POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology. It has also completed Alcohol-Associated Hepatitis (AHFIRM) Phase 2b study.

Contact details

Address:
10240 Bubb Road
CUPERTINO
95014
United States
Telephone:
+1 (408) 7771417
Website:
https://www.durect.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DRRX
ISIN:
US2666055007
Market cap:
$26.21 million
Shares in issue:
31.04 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • James Brown
    President, Chief Executive Officer, Director
  • Timothy Papp
    Chief Financial Officer, Company Secretary
  • Norman Sussman
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.